Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: an Open Label, Randomized Controlled Trial
Who is this study for? Patients with Hepatitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:
• Patients more than 20 years old
• Chronic hepatitis B patients
• Patients who were indicated for hepatitis B virus antiviral therapy
Locations
Other Locations
Taiwan
Taichung Veterans General Hospital
RECRUITING
Taichung
Contact Information
Primary
Teng-Yu Lee, MD, PhD
tylee@vghtc.gov.tw
886-4-23592525
Backup
Hsin-Ju Tsai, MD
a9194024@hotmail.com
886-4-23592525
Time Frame
Start Date: 2019-08-19
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 140
Treatments
Active_comparator: Tenofovir alafenamide group
Study subjects will receive tenofovir alafenamide 25 mg/tab once daily
Active_comparator: Entecavir group
Study subjects will receive entecavir 0.5 mg/tab once daily
Related Therapeutic Areas
Sponsors
Leads: Taichung Veterans General Hospital